Hemostasis profile and lipid metabolism with long-interval use of a desogestrel-containing oral contraceptive

Cachrimanidou, A.-C.; Hellberg, Dan; Nilsson, Staffan; Schoulz, B von; Crona, N.; Siegbahn, Agneta

doi:10.1016/0010-7824(94)90051-5

Cited by 40 publications

(8 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Four RCTs (15,42–44) demonstrated no significant difference in the lipid profiles between the two regimens. Wiegratz 2010 (42) found an increase in total cholesterol, high‐density lipoprotein, triglycerides and very‐low‐density lipoprotein, and a decrease in low‐density lipoprotein over the study period of one year for both groups.…”

Section: Resultsmentioning

confidence: 96%

“…Wiegratz 2010 (42) found an increase in total cholesterol, high‐density lipoprotein, triglycerides and very‐low‐density lipoprotein, and a decrease in low‐density lipoprotein over the study period of one year for both groups. In three RCTs (43–45) the hemostatic parameters during conventional OC administration were compared with the values during continuous administration. In both regimens the pro‐coagulatory factors were elevated, the coagulation inhibitors reduced and the fibrinolysis variables increased, with no significant difference between the two methods of administration.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Continuous use of oral contraceptives: an overview of effects and side‐effects

Hee

Kettner

Vejtorp

2012

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 96%

Section: Resultsmentioning

confidence: 99%

Continuous use of oral contraceptives: an overview of effects and side‐effects

Hee

Kettner

Vejtorp

2012

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

show abstract

“…56,58,71,72,76,79,81,83,85,88,90,97 In contrast, levels of t-PA (antigen) and PAI-1 were all reduced by 25 to 50% and by 30 to 60%, respectively. 50,56,58,70,73,74,76,79,[81][82][83]85,88,90,92 Discrepancies between t-PA activity and antigen levels are frequently reported in studies investigating the impact of COC on the fibrinolytic system. The main explanation is that t-PA (activity) is "doped" by the decrease in PAI-1 (both antigen and activity), the main inhibitor of the fibrinolytic system, which is itself reduced by the COCs.…”

Section: Dynamic Markers Of the Procoagulant Activitymentioning

confidence: 99%

Oral Contraceptives and Venous Thromboembolism: Focus on Testing that May Enable Prediction and Assessment of the Risk

Douxfils

Morimont

Bouvy³

2020

Semin Thromb Hemost

View full text Add to dashboard Cite

Combined oral contraceptives (COCs) induce several changes in the levels of coagulation factors. The levels of procoagulant factors are often increased, while levels of anticoagulant factors are decreased. Fibrinolysis is also affected, even if the effect seems to be more counterbalanced by opposite regulation of profibrinolytic and antifibrinolytic factors. These effects on hemostasis are more pronounced with third- or fourth-generation COC compared with second-generation COC. Venous thromboembolism (VTE) risk increases when multiple risk factors, including genetic and environmental, are present simultaneously. COC use causes changes in coagulation that modify the prothrombotic state induced by preexisting hemostatic alterations in a supra-additive manner. Therefore, testing appears to be of importance not only before implementing COC but also to monitor any potential thrombogenicity induced by COC therapy. Inherited genetic factors, such as factor V Leiden, G20210A prothrombin mutation, antithrombin, protein C or protein S deficiencies, non-O blood group, as well as CYP2C9*2 and the rs4379368 mutations, have all been identified as genetic predictive risk factors of VTE in women. Nevertheless, the screening of these genetic biomarkers is not capable of assessing the phenotypic expression of the risk. This review will focus on the different options for screening the thrombogenic status in this population. Specific attention will be given to the endogenous thrombin potential-based activated protein C resistance, a test aiming at assessing the thrombogenicity induced by hormonal therapies and inherited or acquired thrombophilia.

show abstract

“…Limited information is available on the metabolic effects of continuous or extended OCPs. One small study randomized 30 women to a cyclic versus extended regimen and found no differences in liver proteins, lipoproteins, and hemostatic variables at 0, 3, and 12 months (Cachrimanidou et al 1994). The small increased temporal exposure to synthetic hormones, associated with extended or continuous OCP use, is unlikely to result in signifi cant metabolic differences compared with traditional cyclic administration.…”

Section: Limitations/side Effectsmentioning

confidence: 99%

Evaluation of extended and continuous use oral contraceptives

Wright

Johnson²

2008

TCRM

View full text Add to dashboard Cite

Oral contraceptives are classically given in a cyclic manner with 21 days of active pills followed by 7 days of placebo. In the past 4 years, new oral contraceptives have been introduced which either shorten the placebo time, lengthen the active pills (extended cycle), or provide active pills every day (continuous). These concepts are not new; extended and continuous pills were fi rst studied in the 1960s and 1970s and have been provided in an off-label manner by gynecologists to treat menstrual disorders, such as menorrhagia and dysmenorrhea, and gynecologic disorders, such as endometriosis. Now that extended and continuous combined oral contraceptives are available for all patients, it is critical for providers to understand the physiology, dosing, side effects, and benefi ts of this form of oral contraceptive. This article reviews the history and the potential uses of the new continuous combined oral contraceptive.

show abstract

Hemostasis profile and lipid metabolism with long-interval use of a desogestrel-containing oral contraceptive

Cited by 40 publications

References 29 publications

Continuous use of oral contraceptives: an overview of effects and side‐effects

Continuous use of oral contraceptives: an overview of effects and side‐effects

Oral Contraceptives and Venous Thromboembolism: Focus on Testing that May Enable Prediction and Assessment of the Risk

Evaluation of extended and continuous use oral contraceptives

Contact Info

Product

Resources

About